Table 1 Baseline characteristics of patients with metachronous pulmonary metastases from PDAC
Variables | |
|---|---|
Age, years, median (range) | 69.0 (55.0–80.0) |
Sex, n (%) | |
Male | 15 (56.0) |
Female | 9 (44.0) |
ECOG performance status, n (%) | |
0,1 | 21 (87.5) |
2,3 | 3 (12.5) |
Location, n (%) | |
Head | 17 (70.8) |
Body-tail | 7 (29.2) |
CEA (ng/mL), median (range) | 3.9 (1.2–51.5) |
CA19-9 (U/mL), median (range) | 128.5 (11.0–1185.9) |
Neoadjuvant chemotherapy, n (%) | |
Gemcitabine + S-1 | 2 (8.3) |
Surgical procedure, n (%) | |
PD | 17 (70.8) |
DP | 7 (29.2) |
Portal vein resection, n (%) | 6 (25.0) |
Primary tumour size (mm), median (range) | 31 (6–80) |
Pathologic T category (primary tumour), n (%) | |
T1 | 6 (25.0) |
T2 | 11 (45.8) |
T3 | 7 (29.2) |
Pathologic N category, n (%) | |
N0 | 6 (25.0) |
N1 | 8 (33.3) |
N2 | 10 (41.7) |
Residual tumour category, n (%) | |
R0 | 21 (87.5) |
R1 | 3 (12.5) |
Tumour differentiation, n (%) | |
Well | 9 (37.5) |
Moderate | 11 (45.8) |
Poor | 4 (16.7) |
Pathologic UICC stage, n (%) | |
1A | 5 (20.8) |
1B | 1 (4.2) |
2A | 0 |
2B | 8 (33.3) |
3 | 10 (41.7) |
Adjuvant chemotherapy, n (%) | 21 (87.5) |
S-1 | 14 (58.3) |
Gemcitabine | 4 (16.7) |
Gemcitabine + S-1 | 3 (12.5) |